Clinical trials: Blindness
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Macular Degeneration, Central Visual Impairment
Scotoma Perimetry Oculomotor Training
The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals…
- Trial name
- SPOT (NCT05456581)
- Testing
- 'Scotoma awareness' Training, Control Training
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Ocular Cicatricial Pemphigoid
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness.
- Trial name
- NCT00584935
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Hemianopia
Multisensory Rehabilitation of Hemianopia
The current proposal is to generate "proof of concept" evidence that hemianopia can be successfully rehabilitated in humans when this multisensory rehabilitation paradigm is used.
- Trial name
- NCT04963075
- Testing
- multisensory rehabilitation paradigm
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Diabetic Retinopathy, Diabetic Blindness
Patient Navigator Intervention for Diabetic Retinopathy
This is a pilot study of a patient navigator intervention for people living with diabetes and at high risk of diabetic blindness.
- Trial name
- SEEN (NCT05188703)
- Testing
- Patient Navigation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
One Eye Blindness, Blind Left Eye
Multiplexing Prism Fitting for Field Expansion of Monocular Vision
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye).
- Conditions
- One Eye Blindness, Blind Left Eye, Blind Right Eye
- Trial name
- NCT06027216
- Testing
- Multiplexing Prism
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Age Related Macular Degeneration, Retinitis Pigmentosa
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
This pilot study will evaluate the visual response to infrared (IR) in humans after dark adaptation. The investigators plan to determine which wavelength and intensity the human eye is most sensitive to in healthy and color-blind…
- Conditions
- Age Related Macular Degeneration, Retinitis Pigmentosa, Congenital Stationary Night Blindness, Colorblindness
- Trial name
- NCT02909985
- Testing
- Tungsten halogen light with narrow bandpass filters
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
CLN3-related Disorders, Non-CLN3 Related Low Vision
Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision
Background: CLN3 involves vision loss observed around the preschool years, with eventual progression to blindness within 1-3 years.
- Trial name
- NCT04974307
- Testing
- OrCam MyEye 2
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Leber Congenital Amaurosis 10, Blindness
Extension Study to Study PQ-110-001 (NCT03140969)
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- INSIGHT (NCT03913130)
- Testing
- QR-110
- Where
- 3 sites in United States, Belgium
- Volunteers
- 9 people
- Sponsor
- Laboratoires Thea
Retinitis Pigmentosa, Usher Syndrome Type 2
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
PQ-421a-002 (Helia) is an open-label, extension study to evaluate the safety, tolerability and efficacy of QR 421a (ultevursen) administered via intravitreal (IVT) injection in one or both eyes, in subjects ≥ 12 years of age with…
- Trial name
- HELIA (NCT05085964)
- Testing
- RNA antisense oligonucleotide for intravitreal injection
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Laboratoires Thea
Blindness
Visual Information Restoration and Rehabilitation Via Sensory Substitution Technology in Children
The BrainPort vision device is a visual prosthetic designed for those who are blind. It enables perception of visual information using the tongue and camera system as a paired substitute for the eye.
- Trial name
- NCT03002597
- Testing
- BrainPort V200 Device
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Ellen Mitchell
Advanced Dry Macular Degeneration
Alpha MSH in Ocular Disease
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease.
- Trial name
- NCT03451578
- Testing
- Alpha MSH assay
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Duke University
Idiopathic Intracranial Hypertension
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
Assessing the safety and effectiveness of a 11-βhydroxysteroid dehydrogenase type 1 inhibitor (AZD4017), in a placebo controlled trial, in acute idiopathic intracranial hypertension (IIH) IIH is a condition of young, overweight…
- Trial name
- IIH:DT (NCT02017444)
- Testing
- AZD4017
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Birmingham
Hemianopia, Hemianopsia
Collision Warning Device for Blind and Visually Impaired
This study evaluates a novel collision warning device to help people with severe vision impairment or blindness avoid collisions with obstacles.
- Conditions
- Hemianopia, Hemianopsia, Peripheral Visual Field Defect, Blindness
- Trial name
- NCT03057496
- Testing
- Collision warning device
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy of Prematurity, Retinal Detachment
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be…
- Conditions
- Retinopathy of Prematurity, Retinal Detachment, Blindness
- Trial name
- ROP (NCT00634972)
- Testing
- ACULAR, REFRESH TEARS
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of South Alabama
Blindness
Young Blind Child Melatonin Treatment Study
The primary goal of this study is to identify the presence of desynchronized circadian rhythms in 25 children by measuring melatonin secretion in serial blood or saliva samples, and to rule out any primary sleep disorders.
- Trial name
- NCT00688935
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Oregon Health and Science University
Blindness
Blind Child Melatonin Treatment Study
The primary focus of this five-year study will be to optimize the melatonin dosing regimen for synchronizing the body clocks of blind children to the 24-hour day.
- Trial name
- NCT00691444
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Oregon Health and Science University
Blindness
Blind Elderly Melatonin Treatment Study
The primary focus of this five-year study will be to optimize the melatonin dosing regimen for synchronizing the body clocks of elderly blind individuals to the 24-hour day.
- Trial name
- NCT00692094
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Oregon Health and Science University